Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 13/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673249 | 0.88 | GABRA5 (0.59) | GABRA5ITGA5 | |
| SCHEMBL7802092 | 0.83 | GABRA5 (0.50) | GABRA5ITGA5SMN1; SMN2POLBMDM2 | |
| SCHEMBL7800780 | 0.83 | GABRA5 (0.55) | GABRA5ITGA5SMN1; SMN2LMNA | |
| SCHEMBL15252300 | 0.78 | GABRA5 (0.56) | GABRA5ITGA5 | |
| SCHEMBL2672736 | 0.75 | GABRA5 (0.71) | GABRA5ITGA5 | |
| SCHEMBL2672866 | 0.75 | GABRA5 (0.70) | GABRA5ITGA5 | |
| SCHEMBL2673050 | 0.75 | GABRA5 (0.73) | GABRA5ITGA5 | |
| SCHEMBL2673286 | 0.75 | GABRA5 (0.58) | GABRA5 | |
| SCHEMBL2673773 | 0.74 | GABRA5 (0.58) | GABRA5ITGA5POLB | |
| SCHEMBL7802081 | 0.74 | GABRA5 (0.58) | GABRA5ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | ROCHE PALO ALTO LLC | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885ITGA5 175/4885SMN1; SMN2 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.